[ad_1]
The World Health Organization (WHO) has ensured that there is nothing to be disappointed in with the coronavirus vaccine from the University of Oxford and AstraZeneca. Soumya Swaminathan, the company’s chief scientist, said Thursday that these cases were not new to infectious disease vaccine testing. Side effects of the vaccine are often seen experimentally. Virologists solve that problem quickly too. Therefore, the AstraZeneca ticker test is closed, which means that there is nothing to be disappointed about. The trial will resume soon. The US media reported the news on CNBC.
In the third phase of the clinical trial, the dose of the vaccine showed some complex side effects in the body of a volunteer, according to the British-Swedish firm AstraZeneca. The ticker test was then temporarily suspended. AstraZeneca scientists said that after administering the vaccine dose, an unknown disease appeared in the volunteer’s body. So the ticker test has been closed for security. However, AstraZeneca has not commented on the nature of the disease.
The Oxford vaccine is one of the most widely used vaccine trials in the world. So the sudden shutdown of the ticker test has created frustration.
Soumya, one of the top scientists at the WHO, says there are many ups and downs in vaccine research and application. There is no evidence that any incurable disease has been so easily vaccinated. It is better to notice the shortcomings at the beginning. Then, by correcting the errors, it will be possible to be absolutely sure of the protection of the vaccine in the future.
Soumya Swaminathan said the closing of the AstraZeneca ticker trial was not a bad sign. Rather, it is time to start over. This boost will ultimately pay off. Completely safe and effective vaccines will be able to be distributed to the world in the next few days.
Soumya had previously warned that it would not be the right decision to carry the vaccine before the third-level trial in an emergency. She originally hinted at the covid vaccine in the United States. The United States Food and Drug Administration (FDA) has announced that the country could inject vaccines in an emergency as the number of corona cases and deaths increases. The United States government also accepted the proposal.
Shortly after the FDA announcement, Soumya said that if the vaccine was started before the third stage of the trial, it could have “adverse side effects” on the human body. Three levels of experimental application must be completed after a safety test in the laboratory to determine how safe and effective the vaccine is. The number of volunteers and the ticker dose are also gradually increased from the first to the last of these three levels. From there he proposed the Oxford vaccine. Because, Oxford has been running three-level ticker testing following the rules from the very beginning.
He added that in addition to Great Britain, the vaccine is being tested in several countries around the world, including Brazil, South Africa and India. He is hopeful that the vaccine will have a positive impact in the coming days.
Oxford’s DNA vector vaccine research license has been granted to its partner AstraZeneca. The vaccine, which is made by inactivating a less contagious adenovirus in a chimpanzee’s body, enters a candidate’s body and stimulates B and T cells to produce enough antibodies, according to the team of Oxford virologist Sara Gilbert. Researchers from the Jenner Institute are with Oxford on this study and essay. AstraZeneca was nearing the end of the Oxford Ticker third-level test. If all goes well, they should have brought in the corona vaccine early next year. However, it is feared that vaccination could be delayed due to the postponement of the test. Source: The Wall
[ad_2]
